These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3475108)

  • 1. Comparative effects of vinca alkaloids (VCR, VDS) and epipodophyllotoxin (VP16) on murine myeloblastic leukaemia.
    Yamashita Y; Nara N; Murohashi I; Imai Y; Aoki N
    Br J Cancer; 1987 May; 55(5):517-9. PubMed ID: 3475108
    [No Abstract]   [Full Text] [Related]  

  • 2. The in vitro effect of vincristine on the blast cell renewal in acute myeloblastic leukemia.
    Yamashita Y; Tohda S; Nagata K; Suzuki T; Imai Y; Nara N
    Jpn J Med; 1991; 30(5):412-9. PubMed ID: 1803040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative cell killing and kinetic effects of vincristine or vindesine in mammalian cell lines.
    Hill BT; Whelan RD
    J Natl Cancer Inst; 1981 Aug; 67(2):437-43. PubMed ID: 6943380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter: Epipodophyllotoxin VP 16213 in acute non-lymphoblastic leukaemia.
    Cavalli F; Sonntag R; Brunner KW
    Br Med J; 1975 Oct; 4(5990):227. PubMed ID: 1059494
    [No Abstract]   [Full Text] [Related]  

  • 5. [Enhancement of the effects of anticancer agents on B16 melanoma cells by combination with cepharanthine--I. Alkaloids].
    Kubota R; Kubota K; Yamada S
    Gan To Kagaku Ryoho; 1992 Nov; 19(13):2163-7. PubMed ID: 1444481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine.
    Rivera-Fillat MP; Pallarés-Trujillo J; Domènech C; Grau-Oliete MR
    Br J Pharmacol; 1988 Apr; 93(4):902-8. PubMed ID: 3390658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-resistance of cultured murine leukemia vincristine-resistant P388 cells to vinblastine, vindesine, and bis (N-ethylidene vindesine) disulfide, disulfate.
    Wilkoff LJ; Dulmadge EA
    J Natl Cancer Inst; 1982 Jun; 68(6):1023-6. PubMed ID: 6953266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of snail neurons in developing quantitative ultrastructural parameters for neurotoxic side effects of Vinca antitumor agents.
    Müller LJ; Moorer-van Delft CM; Zijl R; Roubos EW
    Cancer Res; 1990 Mar; 50(6):1924-8. PubMed ID: 2407348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vindesine in the treatment of leukaemia.
    Gökbuget N; Hoelzer D
    Leuk Lymphoma; 1997 Aug; 26(5-6):497-506. PubMed ID: 9389357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of vincristine by vitamin A against drug-resistant mouse leukaemia cells.
    Nogae I; Kikuchi J; Yamaguchi T; Nakagawa M; Shiraishi N; Kuwano M
    Br J Cancer; 1987 Sep; 56(3):267-72. PubMed ID: 3663474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse.
    Dorr RT; Alberts DS
    J Natl Cancer Inst; 1985 Jan; 74(1):113-20. PubMed ID: 3855472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vindesine receptors in cells of a human leukaemia cell line.
    Totsuka K; Oshimi K; Mizoguchi H
    Br J Cancer; 1982 Sep; 46(3):392-6. PubMed ID: 6957239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of murine CFU-C by vindesine: restoration of colony growth by colony stimulating factor.
    Pigoli G; Mangoni L; Caramatti C; Degliantoni G; Rizzoli V
    Int J Cell Cloning; 1983 Jul; 1(3):142-50. PubMed ID: 6609213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental approaches to outcome prediction in acute myeloblastic leukemia.
    McCulloch EA
    Recent Results Cancer Res; 1984; 94():76-92. PubMed ID: 6593778
    [No Abstract]   [Full Text] [Related]  

  • 15. [A randomized controlled study on vindesine and vincristine in combination with prednisolone in the treatment of adult acute lymphocytic leukemia and blastic crisis of chronic myeloid leukemia].
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2500-8. PubMed ID: 6580840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxicity of adriamycin and daunorubicin for normal and leukemia progenitor cells of man.
    Buick RN; Messner HA; Till JE; McCulloch EA
    J Natl Cancer Inst; 1979 Feb; 62(2):249-55. PubMed ID: 310906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive interaction of bisbenzylisoquinoline alkaloid, cepharanthin, with vinca alkaloid agents against human tumors.
    Ono M; Tanaka N
    In Vivo; 1997; 11(3):233-41. PubMed ID: 9239517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Administration of vindesine sulfate for the treatment of malignant hematological tumors].
    Ueda T; Masaoka T; Shibata H; Kubota Y; Saigo K; Kusakabe H; Takubo T; Nakamura H; Yoshitake J; Ishigami S
    Gan To Kagaku Ryoho; 1982 Feb; 9(2):306-15. PubMed ID: 6764103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic inhibitory effects of dipyridamole and vincristine on the growth of human leukaemia and lymphoma cell lines.
    Hirose M; Takeda E; Ninomiya T; Kuroda Y; Miyao M
    Br J Cancer; 1987 Oct; 56(4):413-7. PubMed ID: 3479994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine.
    Mathé G; Misset JL; De Vassal F; Gouveia J; Hayat M; Machover D; Belpomme D; Pico JL; Schwarzenberg L; Ribaud P; Musset M; Jasmin C; De Luca L
    Cancer Treat Rep; 1978 May; 62(5):805-9. PubMed ID: 274996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.